After an incredible run-up in the days after its initial public offering, volatility in Robinhood (NASDAQ:HOOD) is mostly absent. That did not stop the bearish selling on HOOD stock from accelerating after the company posted quarterly results on Oct. 26. Source: OpturaDesign / Shutterstock.com Robinhood fell after posting third-quarter results. What did investors not like?
0 Comments
Jeff Bezos, left, and Elon Musk Getty Images; Reuters The U.S. Federal Court of Claims ruled against Jeff Bezos’ Blue Origin in the company’s lawsuit versus NASA over a lucrative astronaut lunar lander contract awarded to Elon Musk’s SpaceX earlier this year. Federal judge Richard Hertling sided with the defense in his ruling, completing a
0 Comments
The cost of healthcare can be overwhelming. Even with insurance, individuals and families often find themselves spending a significant amount of money on medical costs. The average family of four with employer-provided insurance and an income of $100,000 will likely pay $12,500 in healthcare expenses. This equates to roughly 13% of the family’s income. Flexible
0 Comments
It has been an excellent third-quarter earnings season so far. Of the S&P 500 stocks that have reported earnings, a majority have beaten analyst estimates.  According to Factset Insight, 56% of the index companies have reported earnings so far in Q3 2021. Of those, 82% beat the consensus earnings per share (EPS). That’s higher than
0 Comments
If you’ve read my prior articles on Ocugen (NASDAQ:OCGN), you know full well my heavily bearish view about OCGN stock. What’s the story here? The company is trying to bring Covaxin, a Covid-19 vaccine candidate developed by India’s Bharat Biotech, to the U.S. and Canada. Source: shutterstock.com/PhotobyTawat So far, it’s made little progress obtaining Emergency
0 Comments
CNBC’s Jim Cramer on Friday took comfort in a prediction by Dr. Scott Gottlieb that the pandemic phase of Covid could be over by January. “Dr. Gottlieb basically said the war’s over, and that’s just incredible,” Cramer said. Gottlieb, who had served as FDA chief under former President Donald Trump, is currently a Pfizer board
0 Comments
Big Oil has been out of favor for over a decade. But on the reopen, are the analysts finally bullish? Visit our website: https://www.zacks.com Visit our Stocktwits account: https://stocktwits.com/ZacksResearch Check out our weekly promotion: https://www.zacks.com/promo If you’re interested in our services, please check out Zacks Ultimate: https://www.zacks.com/ultimate/?adid=YOUTUBE&cid=sm-YOUTUBE
0 Comments